Oct 28, 2021
In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre on best practices for using adjunctive treatment for major depressive disorder.
Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MDD
Learning Objectives: After completing this educational activity, you should be better able to:
Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NEI designates this online live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME/CE Credit Types. The following are being offered for this activity:
Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented.
Interviewer
Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA
Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva
Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris
Interviewee
Roger S. McIntyre, MD, FRCPC
Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada
Grant/Research: CIHR/GACD/National Natural Science Foundation of China
Consultant/Advisor: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda
Speakers Bureau: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda
Pre-Interview Author
Sabrina K. Bradbury-Segal, PhD
Medical Writer, Neuroscience Education Institute, Carlsbad, CA
No financial relationships to disclose.
The Planning Committee and Peer Reviewer have no financial relationships to disclose.
Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.
Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture
Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Released: October 21, 2021 CE credit expires: October 21, 2024